Okamoto F, Allen B S, Buckberg G D, Leaf J, Bugyi H
J Thorac Cardiovasc Surg. 1986 Sep;92(3 Pt 2):573-82.
This study tests the hypothesis that the oxygen radical scavenger coenzyme Q10 can be given both intravenously and in the cardioplegic solution and can improve muscle salvage following surgical revascularization. Pilot studies were carried out in dogs undergoing 40 minutes of coronary artery ligation with reperfusion with normal blood, with the heart in the beating, working state. Intravenous infusions of coenzyme Q10 (10 mg/kg) 5 minutes before reperfusion resulted in improved recovery of creatine phosphate, adenosine triphosphate, total adenine nucleotide, and myocardial function reverse estimated by postextrasystolic potentiation, in comparison with the degree of recovery in untreated dogs. Experimental studies were done on 27 dogs undergoing 2 hours of left anterior descending coronary artery occlusion and subsequent reperfusion with and without total vented bypass. Thirteen dogs received intravenous coenzyme Q10 10 minutes before extracorporeal circulation, six received substrate-enriched blood cardioplegic solution with added coenzyme Q10, and six received normal blood reperfusate. Six others had cardioplegic reperfusion without coenzyme Q10. The systolic bulging that occurred during ischemia (ultrasonic crystals) persisted after reperfusion with normal blood (-25% systolic shortening, p less than 0.05), and 44% transmural triphenyltetrazolium chloride nonstaining occurred in the area at risk. Conversely, hearts receiving substrate-enriched blood cardioplegic solution recovered 37% contractility (p less than 0.05), with the least, and only, subendocardial triphenyltetrazolium chloride nonstaining (25% of area at risk) occurring with intravenous coenzyme Q10 before bypass and coenzyme Q10 supplementation of the cardioplegic solution. Intravenous coenzyme Q10, given just before reperfusion (possibly in transit to the operating room), enhances the role of substrate-enriched blood cardioplegic solution (especially when added to the cardioplegic solution) in salvaging ischemic myocardium and allowing immediate functional recovery.
氧自由基清除剂辅酶Q10既可以静脉给药,也可以加入心脏停搏液中,并且能够在外科血管重建术后改善肌肉挽救情况。在经历40分钟冠状动脉结扎并以正常血液再灌注、心脏处于跳动及工作状态的犬身上进行了初步研究。再灌注前5分钟静脉输注辅酶Q10(10毫克/千克),与未治疗的犬相比,磷酸肌酸、三磷酸腺苷、总腺嘌呤核苷酸的恢复情况以及通过期外收缩后增强评估的心肌功能恢复情况均得到改善。对27只经历2小时左前降支冠状动脉闭塞及随后在有或无完全体外循环情况下再灌注的犬进行了实验研究。13只犬在体外循环前10分钟接受静脉辅酶Q10,6只接受添加了辅酶Q10的富含底物血液心脏停搏液,6只接受正常血液再灌注液。另外6只进行无辅酶Q10的心脏停搏再灌注。缺血期间出现的收缩期膨隆(超声晶体)在正常血液再灌注后持续存在(收缩期缩短25%,p<0.05),并且在危险区域出现44%的透壁氯化三苯基四氮唑不着色。相反,接受富含底物血液心脏停搏液的心脏恢复了37%的收缩力(p<0.05),在旁路前静脉给予辅酶Q10并在心脏停搏液中补充辅酶Q10时,内膜下氯化三苯基四氮唑不着色最少且仅出现于危险区域的25%。再灌注前(可能在转运至手术室途中)给予静脉辅酶Q10可增强富含底物血液心脏停搏液(尤其是添加到心脏停搏液中时)在挽救缺血心肌及实现即时功能恢复方面的作用。